Astellas/UMN Complete Inoculations In Phase III Seasonal Influenza Vaccine Study
This article was originally published in PharmAsia News
Astellas Pharmaceuticals and UMN Pharma have completed the inoculation of all subjects in a Phase III trial for ASP7374, a cell culture seasonal influenza vaccine, the companies announced Dec. 11.
You may also be interested in...
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
HBW Market News: FTC Ends Another Supplement Scam, Australia Win For ChromaDex, GOED Report, Herbalife
Herbalife opens 9,200 square-foot training facility in China; GOED's latest annual market report, covering 2017-2018, is available; ChromaDex has two-tear exclusivity for nicotinamide riboside chloride in Australia; and A.S. Research arthritis claims for Synovia end in FTC settlement.
Pharma sells the rights to Germany’s Cheplapharm, which obtained EU/Russia rights in October. Cerecor will acquire Aevi Genomics for $16.1m plus contingent value rights.